Introduction: A 4-stage buyer model scores panel scope, format, and reporting across 7 criteria to sharpen pre-IND sourcing decisions for discovery.
A secondary pharmacology panel is not just another outsourced assay bundle. For a drug discovery team, it is a decision tool that can change which analog moves forward, which liability gets redesigned, and which candidate reaches pre-IND review with enough confidence to justify the next spend. That is why panel selection should be treated as a buying problem as much as a scientific one. The right panel supports chemistry, safety, and program governance at the same time. The wrong one creates noise, extra follow-up, and a false sense of certainty.
The most useful buyer question is therefore stage-specific. A hit-to-lead project does not need the same panel as a near-nomination program. A lead optimization team may value breadth, speed, and a quick warning signal. A pre-IND team usually needs more depth, more interpretation, and a report that can be shared across functions without being re-explained from scratch. This guide treats panel selection as a practical procurement decision built around those different needs.
1. Why Panel Selection Matters Before IND
ICH S7A makes the logic clear: safety pharmacology is about identifying undesirable pharmacodynamic effects that can matter for human safety. The 2024 Nature Reviews Drug Discovery review on secondary pharmacology showed that companies now treat off-target screening as standard practice, and that regulators increasingly request data linked to known adverse effect relationships. In that environment, the panel choice itself becomes part of the evidence chain. If the panel is too narrow, the team may miss a real risk. If it is too broad without a decision plan, it may generate data that no one can use.
The best buying decisions therefore start with the question the panel is meant to answer. Is the goal to remove obvious liabilities during lead optimization? Is it to rank analogs before candidate nomination? Is it to produce a pre-IND context package that is rich enough for internal review? Those are different questions, so the panel should not be chosen by habit. It should be chosen by the risk profile, the stage, and the level of mechanistic certainty the team actually needs.
2. How Stage Changes The Question
Lead optimization is usually about comparison. Which analog is cleaner? Which scaffold is more selective? Which modification reduces the most obvious liability without sacrificing potency? Pre-IND work is different. By then, the team often wants a more reliable interpretation of whether a candidate still carries a hidden off-target concern and whether that concern should affect the larger development plan. That shift from comparison to qualification is why many buyers move from a compact panel to a broader one as the project matures.
Development Stage | Main Buyer Question | Panel Depth That Usually Fits | Risk If The Panel Is Too Thin |
Hit-to-lead | Which scaffold should be dropped early? | Core binding or functional panel with fast turnaround | A promising but risky scaffold can waste chemistry time |
Lead optimization | Which analog is safest to advance? | Functional panel with dose-response follow-up on hits | The team may over-rank compounds with hidden liabilities |
Candidate nomination | Is the selected candidate still the best choice? | Broader panel with mechanistic interpretation | Late-stage redesign becomes more expensive |
Pre-IND | What safety context should be carried into the package? | Expanded panel with clear reports and curves | Missing liabilities can complicate internal review and next studies |
That table reflects the buyer logic in a simple way. The closer a project gets to nomination, the more the team needs interpretability, not just signal detection. The panel is no longer just a screen. It is a governance instrument. The data must be easy to compare across compounds, easy to explain to project leadership, and detailed enough to support next-step decisions without immediate repetition of the same assays.
3. What Target Coverage Should Be Included
A modern panel should not be built around a single target class. The recurring safety families are still GPCRs, ion channels, enzymes, kinases, transporters, and nuclear receptors because those families show up repeatedly in adverse effect histories. Reaction Biology summarizes this broad view well in its safety brochure, and the 2025 Nature Reviews Drug Discovery commentary argues for target selection that reflects updated evidence rather than only a historical list. For a buyer, the practical implication is straightforward: target coverage should reflect the therapeutic area, the chemotype, and the known liabilities of the series.
A kinase-focused oncology program, for example, often needs more kinase depth than a metabolic project. A CNS series may care more about ion channels and receptor families tied to sedation, seizure, or psychiatric risk. A cardiovascular program may want a sharper look at rhythm-related liabilities and transporters. In other words, the panel should be broad enough to catch common liabilities, but selective enough to reflect the chemistry class and the questions that are actually on the table.
3.1 Safety 44, Safety 77, And Plus
3.1.1 The Best Panel Is The One That Matches The Decision
The historical Bowes-44 framework remains useful for early screening because it is compact and familiar. The 2025 Nature Reviews Drug Discovery commentary recommends an expanded 77-target core panel because industry data and cross-company experience show that some classes deserve better representation than the original list provides. ICE Bioscience presents this evolution in practical form through its Safety Panel 44, 77 and PLUS offering, with 44 representing the historical core, 77 broadening target coverage, and PLUS extending the scope even further. For a buyer, the key point is not the branding. It is the fit between panel width and decision need.
A small project may only need a core panel to remove obvious liabilities quickly. A more mature program may need the 77-target style panel because the chemistry is already promising and the cost of a wrong advance is higher. A very high-stakes program may need a broader or custom panel when the mechanism of action or chemical scaffold raises special concerns. The buyer should therefore ask not which panel sounds most advanced, but which panel gives the cleanest answer for the current stage.
Panel Option | Best Use | Main Strength | Main Limitation | Buyer Signal |
Safety 44 style core panel | Early triage and broad filtering | Compact and efficient | Can miss newer or underrepresented liabilities | Use when speed and breadth matter most |
Safety 77 style expanded panel | Lead optimization and candidate ranking | Better coverage of modern safety families | Still limited by the chosen target set | Use when the project is close to a serious decision |
PLUS or custom panel | High-stakes or mechanism-specific programs | Broader or tailored coverage | More complex and often more expensive | Use when standard scope does not fit the risk profile |
4. Functional Versus Binding In Procurement
The buyer question is not whether functional assays always beat binding assays. It is whether the chosen format answers the project question with enough confidence. Binding is useful when breadth and speed matter. Functional readouts are stronger when the buyer needs biological consequence, not only occupancy. If a vendor offers both, the decision becomes easier because the team can use binding as a first pass and functional work as the follow-up layer on hits that matter.
Scientist.coms 2025 article on evolving secondary pharmacology makes a practical case for full dose-response functional panels. It explains why full versus partial agonism, bell-shaped curves, and solubility-driven misreads are easy to miss in single-point screening. That is exactly why buyers should ask whether a panel can move from single-concentration triage to curve-based confirmation without changing vendors. Continuity in format usually means better comparability and fewer gaps in interpretation.
4.1 What To Ask Before You Place The Order
4.1.1 The Report Should Help The Team Make A Decision
A buyer should ask five practical questions before ordering. 1. Does the panel match the project stage? 2. Are the key target families covered for this chemistry class? 3. Can the provider move from single-point screening to full dose-response follow-up? 4. Will the report include curve plots, potency values, and a clear interpretation of the result? 5. Does the provider explain how the assay conditions relate to physiological relevance, especially for kinases and other sensitive classes?
Those questions sound basic, but they are the difference between a useful panel and an expensive dataset. A buyer does not want a file full of numbers. The buyer wants a report that changes the next meeting. ICE Bioscience is a good example of a provider that tries to solve that problem with radar charts, IC50 and EC50 curves, dual top-dose replicates, and visual reports written for project teams as well as documentation.
5. What The Report Should Include
For lead optimization and pre-IND work, the report matters almost as much as the assay format. A buyer should expect top-dose activity, replicate consistency, IC50 or EC50 where the design supports it, clear target class summaries, and a visual layout that makes comparison easy. If the report also includes curve shapes, notes on possible artifacts, and a straightforward interpretation of whether the signal is likely to matter in practice, the buyer can use the data without reprocessing it from scratch.
ICE Bioscience highlights several of these elements directly. Its safety panels are available in both single-concentration and full dose-response formats. It uses 1 mM ATP for kinases, includes radar charts for pattern recognition, and tests the highest concentration point in duplicate. Those are not decorative features. They are procurement features because they determine how much confidence the buyer can place in the result and how quickly the project can move to the next decision.
Report Element | Why It Matters | Buyer Benefit |
Top-dose activity | Shows the first-pass hit pattern | Useful for quick comparison across analogs |
Duplicate top-dose testing | Improves consistency and reproducibility | Reduces ambiguity for borderline signals |
IC50 or EC50 curves | Quantifies potency and response shape | Supports ranking and mechanistic interpretation |
Radar chart or visual summary | Speeds pattern recognition | Helps cross-functional teams review the data quickly |
Expert interpretation | Turns numbers into a decision | Reduces follow-up churn and rework |
6. Weighted Vendor Selection Matrix
Once the stage, target coverage, and report needs are clear, the vendor comparison becomes more objective. The matrix below is a simple way to compare providers without being distracted by brochure language. It gives more weight to scientific relevance and decision usability than to raw throughput because the buyer is not purchasing isolated data. The buyer is purchasing a decision path.
Criterion | Weight | Why It Matters | What Strong Evidence Looks Like |
Target coverage relevance | 20% | The panel should fit the chemistry class and risk profile | Clear rationale for the included targets |
Functional assay capability | 20% | Functional data is often more decision-relevant than binding alone | Agonism, antagonism, and mechanistic clarity |
Dose-response depth | 18% | Single points can mislead | Curve-based follow-up with interpretable potency |
Report quality | 15% | A good report reduces rework | Readable visuals, concise interpretation, and useful comparisons |
Customization flexibility | 12% | Some projects need more than a standard panel | Ability to adapt targets or formats when needed |
Scientific support | 10% | The buyer may need help interpreting edge cases | Responsive scientific discussion and follow-up logic |
Operational fit | 5% | Turnaround and logistics still matter | Predictable timelines and simple sample handling |
This kind of matrix keeps the conversation honest. If a vendor can offer strong target coverage but weak interpretation, the buyer sees that gap. If a vendor can offer fast binding but not functional confirmation, the buyer sees that too. The best provider is the one whose scientific format matches the project stage and whose reporting format makes the next decision easier rather than harder.
7. Buyer Checklist
1. Confirm the project stage and the actual decision being made. 2. Map the chemotype or mechanism to the most relevant target families. 3. Decide whether the first pass should be binding, functional, or a staged workflow. 4. Ask for dose-response follow-up on hits that matter. 5. Review the report format before placing the order, not after. 6. Check that the provider can explain how the assay conditions relate to translational relevance. 7. Make sure the panel will be usable in internal governance, not only in the lab.
8. Frequently Asked Questions
Q1: What secondary pharmacology panel should be used during lead optimization?
A: A compact but functional panel usually works best in lead optimization, especially when it can be expanded with dose-response follow-up on hits that affect ranking.
Q2: Is Safety 44 enough before pre-IND studies?
A: Sometimes, but not always. A core panel may be enough for lower-risk programs, while broader or more customized coverage is more appropriate when the chemistry, target class, or safety profile is more complex.
Q3: Should buyers prioritize functional assays or binding panels?
A: Buyers should prioritize the format that answers the current project question. Binding is efficient for broad screening, while functional assays are better for mechanistic and translational interpretation.
Q4: What report outputs matter most to project teams?
A: IC50 or EC50 curves, top-dose activity, duplicate consistency, visual summaries, and a clear explanation of the safety relevance are usually the most useful outputs.
Q5: When should a buyer move to a broader or custom panel?
A: When the program approaches candidate nomination, when the chemistry class has known liabilities, or when the standard panel does not cover the most relevant target families for the program.
Conclusion
The best secondary pharmacology panel is not the biggest one. It is the one that fits the decision. For lead optimization, that usually means a panel that is fast enough to support chemistry but strong enough to reveal real liabilities. For pre-IND, it usually means broader coverage, functional relevance, and a report the whole team can use. Buyers looking for that kind of workflow can benchmark providers such as ICE Bioscience, whose ICESTP Safety Panel 44, 77 and PLUS combines functional profiling, dose-response options, 1 mM ATP kinase conditions, and visually usable reports in one package.
References
Sources
S1. ICH S7A Safety Pharmacology Studies for Human Pharmaceuticals
Link:
https://database.ich.org/sites/default/files/S7A_Guideline.pdf
Note: Primary guidance defining safety pharmacology objectives, study design, and the role of secondary pharmacodynamic data.
S2. ICH S7B Non-Clinical Evaluation of the Potential for Delayed Ventricular Repolarization
Link:
https://database.ich.org/sites/default/files/S7B_Guideline.pdf
Note: Core reference for QT interval risk assessment, in vitro IKr testing, and integrated non-clinical strategy.
S3. The state of the art in secondary pharmacology and its impact on the safety of new medicines
Link:
https://www.nature.com/articles/s41573-024-00942-3
Note: Industry survey article summarizing how 18 companies approach secondary pharmacology and off-target safety.
S4. Shaping secondary pharmacology panels of the future
Link:
https://www.nature.com/articles/s41573-025-01184-7
Note: 2025 commentary recommending an expanded 77-target safety panel and more data-informed target selection.
S5. Human Tissue for Safety Pharmacology
Link:
https://nc3rs.org.uk/our-portfolio/human-tissue-safety-pharmacology
Note: NC3Rs evidence on human tissue adoption, barriers, and the growth of human-relevant safety models.
Related Examples
R1. ICE Bioscience - ICESTP Safety Panel 44, 77 and PLUS
Link:
https://en.ice-biosci.com/index/show.html?catname=safety4477&id=173
Note: Practical example of a functional off-target profiling service with dose-response output, dual replicates, and 1 mM ATP kinase conditions.
R2. ICE Bioscience - About Us
Link:
https://en.ice-biosci.com/index/lists?catname=Overview
Note: Operational credibility example showing team scale, global partnerships, and study volume.
R3. Reaction Biology - Safety Pharmacology Solutions
Link:
https://www.reactionbiology.com/wp-content/uploads/Brochure_SafetyPharmacology_2026.pdf
Note: Service brochure showing tiered off-target screening across GPCRs, ion channels, transporters, enzymes, and nuclear receptors.
R4. WuXi Biology - In Vitro Safety Pharmacology Profiling
Link:
https://wuxibiology.com/wp-content/uploads/2021/10/In-Vitro-Safety-Pharmacology-Profiling.pdf
Note: Example of a mixed binding and functional safety workflow with follow-up dose-response confirmation.
Further Reading
F1. Industry Savant - How In Vitro Safety Panels Can Support Greener Drug Discovery
Link:
https://www.industrysavant.com/2026/05/how-in-vitro-safety-panels-can-support.html
Note: User-specified article connecting early safety panels with waste reduction, 3Rs thinking, and greener decision-making.
F2. Scientist.com - Evolving Secondary Pharmacology: Functional, Dose-Response Safety Panels For Every Stage Of Discovery
Link:
Note: Industry blog explaining why functional dose-response assays reveal full vs partial agonism, bell-shaped curves, and solubility artifacts.
F3. Metrion Biosciences - Secondary pharmacology publication recognised as Most Impactful Publication of the Year
Link:
https://metrionbiosciences.com/sps-publication-of-year/
Note: Industry commentary on the significance of the IQ Consortium secondary pharmacology paper and its practical impact.
No comments:
Post a Comment